Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.

scientific article published in August 2010

Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/JAMA.2010.1205
P698PubMed publication ID20736474

P50authorBruce M. PsatyQ30429993
David S SiscovickQ86839898
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectbiasQ742736
P304page(s)897-898
P577publication date2010-08-01
P1433published inThe Journal of the American Medical AssociationQ1470970
P1476titleMinimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.
P478volume304

Reverse relations

cites work (P2860)
Q51643878A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Q30887169A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry
Q35883274A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age ≥ 65 years
Q38387733Active-comparator design and new-user design in observational studies
Q60044793Acute kidney injury in postoperative shock: is hyperoncotic albumin administration an unrecognized resuscitation risk factor?
Q39256176Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study.
Q30661964Adrenaline (epinephrine) dosing period and survival after in-hospital cardiac arrest: a retrospective review of prospectively collected data
Q30696956An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease
Q36851454Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction
Q37626595Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices.
Q43430988Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.
Q36072330Clinical and economic outcomes of thyroid surgery in elderly patients: a systematic review
Q35680854Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent
Q40280177Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.
Q33997802Comparative effectiveness of 2 β-blockers in hypertensive patients
Q41299360Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals
Q38969469Comparative effectiveness of mycophenolate mofetil for the treatment of childhood-onset proliferative lupus nephritis
Q28732445Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop
Q45937309Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort.
Q36947797Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort stu
Q34647118Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study
Q35846647Conducting comparative effectiveness research on medications: the views of a practicing epidemiologist from the other Washington
Q36008497Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment
Q36573102Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study
Q35658906Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study
Q33730879Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease
Q34020625Etomidate, adrenal function, and mortality in critically ill patients
Q38171873Evaluating methodological assumptions in comparative effectiveness research: overcoming pitfalls
Q35136444Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study
Q36455050Exposure to oral bisphosphonates and risk of cancer
Q36925442External adjustment sensitivity analysis for unmeasured confounding: an application to coronary stent outcomes, Pennsylvania 2004-2008.
Q35876254Fracture risk in men with prostate cancer: a population-based study.
Q35991921Fracture risk in women with breast cancer: a population-based study.
Q55299717Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis.
Q37594735Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity
Q28482730Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients
Q47548156New statin use and left ventricular structure: Estimating long-term associations in the Multi-Ethnic Study of Atherosclerosis (MESA).
Q28703603Observational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions?: comment on "Comparative effectiveness of 2 β-blockers in hypertensive patients"
Q30538243Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease
Q97568852Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study
Q24595632Oral contraceptives and the risk of gallbladder disease: a comparative safety study
Q35140167Propensity score matching: a conceptual review for radiology researchers
Q90521116Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years
Q90567938Relationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis
Q58695012Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication
Q57470112Risks of Benzodiazepines in Chronic Obstructive Pulmonary Disease with Comorbid Posttraumatic Stress Disorder
Q34156032The association of episiotomy with obstetric anal sphincter injury--a population based matched cohort study
Q34476667The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study
Q37731789The challenges of comparing results between placebo controlled randomized trials and non-experimental new user, active comparator cohort studies: the example of olmesartan
Q39213494The use of epidural analgesia for intrapartum pain relief in publicly funded healthcare
Q64134862Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia

Search more.